HEPA Stock - Hepion Pharmaceuticals, Inc.
Unlock GoAI Insights for HEPA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-19,346,578 | $-48,447,954 | $-45,488,726 | $-30,403,309 | $-20,146,075 |
| Net Income | $-13,192,420 | $-48,926,042 | $-42,200,049 | $-32,722,168 | $-20,353,938 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-107.35 | $-616.07 | $-594.75 | $-465.52 | $-2103.70 |
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Visit WebsiteEarnings History & Surprises
HEPAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 6, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | — | $-0.04 | — | — |
Q3 2025 | Aug 15, 2025 | — | $-0.09 | — | — |
Q2 2025 | May 19, 2025 | — | $-2.15 | — | — |
Q2 2025 | Apr 8, 2025 | $-98.50 | $-11.12 | +88.7% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-95.00 | $-36.00 | +62.1% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-185.50 | $-34.00 | +81.7% | ✓ BEAT |
Q2 2024 | Apr 16, 2024 | $-131.50 | $-121.00 | +8.0% | ✓ BEAT |
Q1 2024 | Mar 25, 2024 | $-2.63 | $-2.42 | +8.0% | ✓ BEAT |
Q4 2023 | Nov 20, 2023 | $-134.00 | $-137.00 | -2.2% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-3.32 | $-184.00 | -5442.2% | ✗ MISS |
Q2 2023 | May 12, 2023 | $-3.60 | $-174.00 | -4733.3% | ✗ MISS |
Q2 2023 | Apr 10, 2023 | $-0.13 | $-0.13 | 0.0% | = MET |
Q4 2022 | Nov 14, 2022 | $-0.17 | $-110.00 | -64605.9% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.12 | $-0.26 | -116.7% | ✗ MISS |
Q2 2022 | Apr 8, 2022 | $-0.12 | $-0.13 | -8.3% | ✗ MISS |
Q1 2022 | Jan 3, 2022 | — | $-2.55 | — | — |
Q4 2021 | Nov 15, 2021 | $-0.19 | $-120.00 | -63057.9% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | — | $-100.00 | — | — |
Q2 2021 | May 14, 2021 | $-0.20 | $-120.00 | -59900.0% | ✗ MISS |
Latest News
Frequently Asked Questions about HEPA
What is HEPA's current stock price?
What is the analyst price target for HEPA?
What sector is Hepion Pharmaceuticals, Inc. in?
What is HEPA's market cap?
Does HEPA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to HEPA for comparison